Press Releases May 28, 2026 08:30 AM

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals to Feature Management at 2026 Jefferies Global Healthcare Conference

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
LXRX

Lexicon Pharmaceuticals announces that its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference, highlighting the company's ongoing drug development efforts across multiple therapeutic areas including neuropathic pain, hypertrophic cardiomyopathy, obesity, and other cardiometabolic conditions.

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
LXRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lexicon Pharmaceuticals will present at a major healthcare investment conference, providing exposure to investors and analysts.
  • The company is advancing a diverse pipeline with candidates targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolic disorders.
  • The event will be available live and via replay on the company website, enhancing accessibility for stakeholders.

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.

The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.

About Lexicon Pharmaceuticals    
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.   

For Media Inquiries: 
Dave Belian 
Lexicon Pharmaceuticals, Inc. 
lexinvest@lexpharma.com  
  
For Investor Inquiries: 
Lisa DeFrancesco 
Lexicon Pharmaceuticals, Inc. 
lexinvest@lexpharma.com 


Risks

  • Clinical and regulatory risks inherent in drug development could impact future progress and approvals.
  • Market competition in pharmaceuticals and biotechnologies may affect Lexicon's commercial success.
  • Investor sentiment may be tempered if the presentation lacks new or substantial data updates.

More from Press Releases

Axe Compute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Sep 11, 2026 EverCommerce Announces an Increase and Extension of its Share Repurchase Program Sep 11, 2026 Grupo Aeroportuario del Pacifico Announces the Execution of Bank Credit Facilities Totaling Ps. 8,000 Million Sep 11, 2026 Eastern International Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 11, 2026 ArrowMark Financial Corp. Announces Q2 Results and Special Distribution of $0.10 and Monthly Cash Distribution of $0.15 per Share for September 2026 Sep 11, 2026